Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Nektar Therapeutics (NKTR) Tops Q2 EPS by 17c
August 8, 2019 4:19 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.63), $0.17 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $23.3 million versus the consensus estimate of $26.65 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More